EGFR G719X

Osimertinib is also an option- based on the UNICORN international series we participated in published @JTOonline For G719X, ORR was 47%, mPFS 8.8 months #lcsm (@Latinamd)

2/ @LeXiuning @MDAndersonNews on EGFR mutations: ▪️EGFR mutations ~10-20% NSCLC pts in Europe/N America, & up to 50% of patients in Asia ▪️Exon 19 del & exon 21 L858R most common (~85-90%) ▪️🔑 Most frequent uncommon mutations to know: G719X, S768I, L861Q, & exon 20 insertions (@esinghimd)

Retrospective analysis of osimertinib in 50 pts with atypical #EGFR NSCLC in #JTOCRR. Median time to d/c 17.2m for L861Q, 7.8m for G719X, 1.5m for exon 20 insertion. Afatinib is the approved standard for atypical; amivantamab and mobocertinib for ex20ins. https://t.co/kQiqpEJYTZ (@StephenVLiu)

🚨🚨 Check out our latest collaboration: #UNICORN: UNcommon EGFR mutations: International Case series on efficacy of #osimertinib in 1st liNe J Bair et al. ▶️N=60, G719X L861Q & T790M ▶️ORR 61%, mOS 24.5m. compound EGFR+ did better @EGFRResisters #lcsm https://t.co/7CqrcJpiXr (@Latinamd)

In this multi-center, retrospective study @JTOonline for uncommon EGFR mutation (n=60), osimertinib demonstrated an ORR of 61% (44% for denovo T790M, 47% for G719X ORR & 80% for L861Q) Md PFS 9.5 mo Md DOR 17.4 mo & Md OS of 24.5 mo #LCSM @OncoAlert https://t.co/XxvURqgISg (@dipeshuprety4)

Osimertinib in NSCLC w uncommon EGFR mutns @JTOonline: - 60pt retrosp study, overall ORR 66% - G719X ORR 47% mPFS 8.8m mDOR 9.1m - L861Q ORR 80% mPFS 16m mDOR 16m - de novo T790M ORR 44% mPFS 12.7m mDOR 46.2m ?⬇️ORR T790M than expected, important study https://t.co/B3kpq7AKbR (@DrJNaidoo)

Retrospective report @Annals_Oncology from the national Network of Genomic Medicine in Germany describes 856 NSCLC cases with atypical #EGFR mutations. Includes G719X, S7681, L861Q, exon 20 insertions and rare point mutations with clinical outcomes. #LCSM https://t.co/2benHuhrA7 (@StephenVLiu)

#WCLC20 Results from the SUMMIT basket study of neratinib - specifically the #EGFR exon 18 mutant NSCLC cohort. Exon 18 accounts for about 5% of EGFR mutations, most commonly G719X. #LCSM @IASLC @OncoAlert (@StephenVLiu)

While there is more data for G719X with afatinib, the presence of brain mets and existence of data showing benefit of osimertinib for this and other atypical EGFR mutations would point me towards osi here (@PatelOncology)